DK3160948T3 - Benzoxazinonamider som modulatorer af mineralocorticoidreceptorer - Google Patents
Benzoxazinonamider som modulatorer af mineralocorticoidreceptorer Download PDFInfo
- Publication number
- DK3160948T3 DK3160948T3 DK15736015.7T DK15736015T DK3160948T3 DK 3160948 T3 DK3160948 T3 DK 3160948T3 DK 15736015 T DK15736015 T DK 15736015T DK 3160948 T3 DK3160948 T3 DK 3160948T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzoxazin
- dihydro
- oxo
- mmol
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (10)
1. Forbindelse med formlen (I) dXu HN? o hvori: R1 er valgt blandt CONH2 og CONHCH3, og R2 er valgt blandt H, F, Cl og Br eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf, hvori: R1 er CONHCH3, og R2 er valgt blandt H, F, Cl og Br.
3. Forbindelse ifølge krav 1 eller farmaceutisk acceptabelt salt deraf, hvori: R1 er CONHCH3, og R2 er F.
4. Forbindelse ifølge krav 1, der er valgt blandt: 2 —{4 —[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl)carbonyl]-3,4- dihydro-2H-l,4-benzoxazin-3-yl} acetamid N-methyl-2-{4 —[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid N-methyl-2-{ (3S)—4—[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid N-methyl-2-{(3R)-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{7-fluor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{(3S)-7-fluor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{(3R)-7-fluor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{7-fluor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -limet hyl acet amid 2-{ (3S)-7-fluor-4-[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{(3R)-7-fluor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{7-chlor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{(3S)-7-chlor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{(3R)-7-chlor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{7-chlor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{ (3S)-7-chlor-4-[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{(3R)-7-chlor-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{7-brom-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{ (3 S)-7-brom-4-[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{(3R)-7-brom-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}acetamid 2-{7-brom-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{ (3 S)-7-brom-4-[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl) carbonyl] - 3,4-dihydro-2H-l, 4-benzoxazin-3-yl} -lime thy lace t amid 2-{(3R)-7-brom-4-[(3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl)carbonyl]-3,4-dihydro-2H-l,4-benzoxazin-3-yl}-N-methylacetamid eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge krav 1, som er 2-{ (3S)-7-fluor-4-[ (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamid.
6. Farmaceutisk formulering, der omfatter en forbindelse med formlen (I) eller et farmaceutisk acceptabelt salt af en forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 5 og en farmaceutisk acceptabel bærer, excipiens eller fortyndingsmiddel
7. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt af en forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 5 til anvendelse inden for terapi.
8. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt af en forbindelse med formel (I) ifølge et hvilket som helst af kravene 1 til 5 til anvendelse inden for behandling og/eller forebyggelse af kardiovaskulær sygdom.
9. Forbindelse til anvendelse ifølge krav 8, hvori den kardiovaskulære sygdom er hjertesvigt.
10. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt af en forbindelse med formel (I) ifølge et hvilket som helst af kravene 1 til 5 til anvendelse inden for behandling og/eller forebyggelse af kronisk nyresygdom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 | |
| PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3160948T3 true DK3160948T3 (da) | 2019-02-18 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15736015.7T DK3160948T3 (da) | 2014-06-30 | 2015-06-26 | Benzoxazinonamider som modulatorer af mineralocorticoidreceptorer |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (da) |
| EP (1) | EP3160948B1 (da) |
| JP (1) | JP6368383B2 (da) |
| KR (1) | KR102012222B1 (da) |
| CN (1) | CN106536491B (da) |
| AR (1) | AR101036A1 (da) |
| AU (1) | AU2015282450C1 (da) |
| CA (1) | CA2953655C (da) |
| CY (1) | CY1121596T1 (da) |
| DK (1) | DK3160948T3 (da) |
| EA (1) | EA029518B1 (da) |
| ES (1) | ES2707726T3 (da) |
| HR (1) | HRP20190147T1 (da) |
| HU (1) | HUE042370T2 (da) |
| LT (1) | LT3160948T (da) |
| ME (1) | ME03316B (da) |
| MX (1) | MX367404B (da) |
| PL (1) | PL3160948T3 (da) |
| PT (1) | PT3160948T (da) |
| RS (1) | RS58274B1 (da) |
| SI (1) | SI3160948T1 (da) |
| SM (1) | SMT201900039T1 (da) |
| TR (1) | TR201900659T4 (da) |
| TW (1) | TWI677498B (da) |
| UY (1) | UY36195A (da) |
| WO (1) | WO2016001631A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3160948T3 (pl) * | 2014-06-30 | 2019-04-30 | Astrazeneca Ab | Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych |
| AU2019304032B2 (en) | 2018-07-19 | 2021-12-09 | Astrazeneca Ab | Methods of treating HFpEF employing dapagliflozin and compositions comprising the same |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| EP4021507A1 (en) * | 2019-08-30 | 2022-07-06 | AstraZeneca AB | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| MX2023015144A (es) * | 2021-06-15 | 2024-01-22 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivados de benzoxazinona. |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| IL319212A (en) | 2022-09-01 | 2025-04-01 | Astrazeneca Ab | Combination of SGLT2 inhibitors and mineralocorticoid receptor modulators for use in the treatment of heart and kidney disease |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1385835A1 (en) * | 2001-04-23 | 2004-02-04 | Astrazeneca AB | Benzoxazinone derivatives for use in the treatment of angiogenesis |
| MXPA05006742A (es) * | 2002-12-20 | 2005-09-08 | Warner Lambert Co | Benzoxazinas y derivados de las mismas como inhibidores de fosfoinositido-3-quinasas. |
| CA2581327A1 (en) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Intracellular receptor modulator compounds and methods |
| EP1778242A4 (en) * | 2004-07-28 | 2010-10-20 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDHORMONE NUCLEAR RECEPTORS |
| AR056893A1 (es) | 2005-12-28 | 2007-10-31 | Takeda Pharmaceutical | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| RS20090208A (sr) | 2006-10-31 | 2010-06-30 | Pfizer Products Inc. | Pirazolin jedinjenja kao antagonisti mineralokortikoid receptora |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| AU2008230115A1 (en) | 2007-03-23 | 2008-10-02 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor modulators |
| PT2133330E (pt) | 2007-04-09 | 2014-03-31 | Daiichi Sankyo Co Ltd | Atropisómero de derivado de pirrole |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| EP2303873A4 (en) * | 2008-06-18 | 2012-01-04 | Astrazeneca Ab | BENZOXAZINE DERIVATIVES AS A BETA2 ADRENORE RECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISEASES |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| CA2751901C (en) | 2009-03-12 | 2013-08-06 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| EP2417121A1 (en) | 2009-04-10 | 2012-02-15 | Pfizer Inc. | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| US8979337B2 (en) | 2010-05-11 | 2015-03-17 | Koninklijke Philips N.V. | Lighting module |
| EP2594554A4 (en) | 2010-07-13 | 2014-01-15 | Dainippon Sumitomo Pharma Co | BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS |
| US8722709B2 (en) | 2010-11-10 | 2014-05-13 | Boehringer Ingelheim International Gmbh | Mineralocorticoid receptor antagonists |
| PL3160948T3 (pl) * | 2014-06-30 | 2019-04-30 | Astrazeneca Ab | Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych |
-
2015
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/da active
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3160948T3 (da) | Benzoxazinonamider som modulatorer af mineralocorticoidreceptorer | |
| JP7168773B2 (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
| AU2016299484B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP5564036B2 (ja) | ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体 | |
| JP6211530B2 (ja) | 含窒素複素環化合物 | |
| KR101738866B1 (ko) | 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도 | |
| CA3133753A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
| CN115087440A (zh) | Trpml调节剂 | |
| KR20180016485A (ko) | 무스카린성 m2 수용체의 양성 알로스테릭 조정제 | |
| EP2194051B1 (en) | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | |
| Hu et al. | Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists | |
| AU2019230859B2 (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
| EP2501233B1 (en) | Quinazoline compounds | |
| CZ281714B6 (cs) | Piperidylmethylsubstituované deriváty chromanu | |
| HK1237338A1 (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| HK1237338B (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| EP2470022A1 (en) | Compounds and methods | |
| KR20170106483A (ko) | 테트라히드로피라닐 벤즈아미드 유도체 |